Asset Details
Do you wish to reserve the book?
Clinical Pharmacokinetics and Pharmacodynamics of Safinamide
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical Pharmacokinetics and Pharmacodynamics of Safinamide
Do you wish to request the book?
Clinical Pharmacokinetics and Pharmacodynamics of Safinamide
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical Pharmacokinetics and Pharmacodynamics of Safinamide
2017
Overview
The symptoms of Parkinson’s disease (PD) reflect disruptions of a number of brain neurotransmitter systems of varying type and degree. Pharmacological agents with multiple neurochemical mechanisms of action are therefore promising candidates for countering these problems and providing comprehensive symptomatic relief for patients. The pharmacological profile of safinamide includes reversible monoamine oxidase B inhibition, blockage of voltage-dependent Na
+
channels, modulation of Ca
2+
channels, and inhibition of glutamate release. Safinamide is administered once daily at oral doses of 50–100 mg; it is well-tolerated and safe. Clinical trials have found that it ameliorates motor symptoms when added to established levodopa or single dopamine receptor agonist therapy. The future role of safinamide in PD may be that it enables a reduction in the dosage of dopamine replacement therapies, thereby reducing the adverse effects associated with these treatments. The clinical convenience (once-daily administration), safety, and tolerability of safinamide are better than those of dopamine receptor agonists. The introduction of safinamide reflects a change of approach to drug development for anti-parkinsonian agents in that its broad spectrum of action corresponds to the multiple heterogeneous alterations of brain neurochemistry in PD, rather than being targeted at a single receptor type or neurochemical process. Safinamide is a promising new instrument for the effective symptomatic therapy of PD.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
Alanine - analogs & derivatives
/ Animals
/ Antiparkinson Agents - pharmacokinetics
/ Antiparkinson Agents - therapeutic use
/ Benzylamines - pharmacokinetics
/ Benzylamines - therapeutic use
/ Dopamine
/ Enzymes
/ Humans
/ Medicine
/ Monoamine Oxidase - metabolism
/ Monoamine Oxidase Inhibitors - pharmacokinetics
/ Monoamine Oxidase Inhibitors - therapeutic use
/ Parkinson Disease - drug therapy
